Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological

被引:0
作者
Kim, Ji Min [1 ]
Choi, Euno [1 ]
Sung, Sun Hee [1 ]
Jo, Jungmin [2 ]
Lee, Dong-Hyeon [3 ]
Park, Sanghui [1 ]
机构
[1] Ewha Womans Univ, Mokdong Hosp, Coll Med, Dept Pathol, Seoul, South Korea
[2] Ewha Womans Univ, Mokdong Hosp, Div Hematol Oncol, Dept Internal Med, Seoul, South Korea
[3] Ewha Womans Univ, Sch Med, Med Ctr, Dept Urol, Seoul, South Korea
关键词
Genitourinary Cancer; 22; 2; rights Bladder cancer; Histological subtype; Neoadjuvant chemotherapy; Pathologic complete response (pCR); DW-MRI; MICROPAPILLARY UROTHELIAL CARCINOMA; RADICAL CYSTECTOMY; CLINICAL-OUTCOMES; SURVIVAL; EPIDEMIOLOGY; METAANALYSIS; PROGNOSIS; CISPLATIN; PREDICT; PT0;
D O I
10.1016/j.clgc.2023.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated pathologic features that may affect response to neoadjuvant chemotherapy (NAC) and response evaluation on pelvis diffusion-weighted magnetic resonance imaging (DW-MRI) after NAC in clinically muscle-invasive bladder cancer. The concordance and discordance between MRI and RC findings occurred in 68.3% and 31.7% of cases, respectively. In particular, plasmacytoid urothelial carcinoma showed the largest discrepancy between MRI and radical cystectomy findings after NAC due to its unique invasion pattern. Introduction: We aimed to provide a pathological perspective on the management of muscle-invasive bladder cancer (MIBC) by correlating the prechemotherapy transurethral resection of bladder tumor findings and postchemotherapy radiologic evaluation with final radical cystectomy (RC) findings. Materials and Methods: This retrospective study included 79 MIBC patients treated with neoadjuvant chemotherapy (NAC) and RC. Pelvic diffusion-weighted magnetic resonance imaging (DW-MRI) and pathologic reports were retrieved from our institutional database. All pathology slides were reviewed based on diagnostic cr iter ia with high interobserver reproducibility. Results: Pathologic complete response (pCR) was confirmed in 32 patients (40.5%). The concordance and discordance between MRI and RC findings occurred in 68.3% and 31.7% of cases, respectively. The 21.5% of cases that were clinical CR (cCR) on MRI actually achieved pCR on RC specimens and 46.8% of cases that were non-cCR on MRI were actually non-pCR on RC specimens. In 19.0% of cases, RC findings were pCR, but MRI demonstrated residual tumor and the opposite was 12.7%. The greatest discrepancy between the 2 methods (75%, 3/4) was for the plasmacytoid subtype. Plasmacytoid histology was the most common histological subtype identified in RC specimens after NAC, followed by micropapillary and squamous histologies. Conclusions: We found that all cases with plasmacytoid and micropapillary subtypes, and squamous differentiation did not show pCR. In particular, the largest discrepancy between MRI findings and RC pathology after NAC was seen in the plasmacytoid subtype. An accurate pathologic diagnosis based on strict criteria to identify histological subtypes of MIBC is necessary for proper treatment.
引用
收藏
页码:224 / 236
页数:13
相关论文
共 51 条
[1]  
Abol-Enein H, 2003, LANCET, V361, P1927
[2]   Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes [J].
Abufaraj, Mohammad ;
Foerster, Beat ;
Schernhammer, Eva ;
Moschini, Marco ;
Kimura, Shoji ;
Hassler, Melanie R. ;
Preston, Mark A. ;
Karakiewicz, Pierre I. ;
Remzi, Mesut ;
Shariat, Shahrokh F. .
EUROPEAN UROLOGY, 2019, 75 (04) :649-658
[3]   Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer [J].
Ahmed, Shimaa Abdalla ;
Taher, Mohamed Gamal Ameen ;
Ali, Wageeh A. ;
Ebrahem, Mohamed Abd El Salam .
ABDOMINAL RADIOLOGY, 2021, 46 (06) :2712-2721
[4]   The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: A systematic review [J].
Alvarez-Maestro, Mario ;
Chierigo, Francesco ;
Mantica, Guglielmo ;
Quesada-Olarte, J. M. ;
Carrion, D. M. ;
Gomez-Rivas, Juan ;
Pinto-Marin, Alvaro ;
Bazan, Alfredo Aguilera ;
Martinez-Pineiro, Luis .
ARAB JOURNAL OF UROLOGY, 2022, 20 (01) :1-13
[5]  
Aron Manju, 2022, Surg Pathol Clin, V15, P661, DOI [10.1016/j.path.2022.08.003, 10.1016/j.path.2022.08.003]
[6]   European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) [J].
Babjuk, Marko ;
Burger, Maximilian ;
Capoun, Otakar ;
Cohen, Daniel ;
Comperat, Eva M. ;
Escrig, Jose L. Dominguez ;
Gontero, Paolo ;
Liedberg, Fredrik ;
Masson-Lecomte, Alexandra ;
Mostafid, A. Hugh ;
Palou, Joan ;
van Rhijn, Bas W. G. ;
Roupret, Morgan ;
Shariat, Shahrokh F. ;
Seisen, Thomas ;
Soukup, Viktor ;
Sylvester, Richard J. .
EUROPEAN UROLOGY, 2022, 81 (01) :75-94
[7]   Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review [J].
Barone, Biagio ;
Calogero, Armando ;
Scafuri, Luca ;
Ferro, Matteo ;
Lucarelli, Giuseppe ;
Di Zazzo, Erika ;
Sicignano, Enrico ;
Falcone, Alfonso ;
Romano, Lorenzo ;
De Luca, Luigi ;
Oliva, Francesco ;
Mirto, Benito Fabio ;
Capone, Federico ;
Imbimbo, Ciro ;
Crocetto, Felice .
CANCERS, 2022, 14 (10)
[8]   Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? [J].
Basu, Arnab ;
Sadeghi, Sarmad .
EUROPEAN UROLOGY FOCUS, 2020, 6 (04) :623-626
[9]   Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data [J].
Bono, AV ;
Goebell, PJ ;
Groshen, S ;
Lehmann, J ;
Studer, U ;
Torti, FM ;
Abol-Enein, H ;
Bassi, P ;
Boyer, M ;
Coppin, CML ;
Cortesi, E ;
Hall, RR ;
Horwich, A ;
Malmström, PU ;
Martínez-Piñeiro, JA ;
Sengelov, L ;
Sherif, A ;
Wallace, DMA ;
Clarke, NW ;
Roberts, JT ;
Sylvester, R ;
Parmar, MKB ;
Stewart, LA ;
Tierney, JF ;
Vale, CL .
EUROPEAN UROLOGY, 2005, 48 (02) :189-201
[10]   Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline [J].
Chang, Sam S. ;
Bochner, Bernard H. ;
Chou, Roger ;
Dreicer, Robert ;
Kamat, Ashish M. ;
Lerner, Seth P. ;
Lotan, Yair ;
Meeks, Joshua J. ;
Michalski, Jeff M. ;
Morgan, Todd M. ;
Quale, Diane Z. ;
Rosenberg, Jonathan E. ;
Zietman, Anthony L. ;
Holzbeierlein, Jeffrey M. .
JOURNAL OF UROLOGY, 2017, 198 (03) :552-559